Patents Assigned to Virginia Commonwealth University
  • Patent number: 9474493
    Abstract: A method and apparatus are used to compare in real-time an intended radiation treatment plan with a delivered plan. Markers are arranged, on a subject receiving radiation, at three-dimensional (3D) positions between a two dimensional radiation detector and a radiation source and are used to reconstruct the actual position of a high dose rate (HDR) source in three-dimensional (3D) space. The detected position is compared with the intended radiation path of the treatment plan. Adjustments can be made to the treatment plan if the detected position and the intended path do not correspond.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 25, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Dorin A. Todor, Aditya A. Bondal
  • Publication number: 20160297873
    Abstract: Pharmaceutical compositions and methods for the treatment of DENND1 A. V2 related disorders, such as PCOS, are provided. In particular, humanized and mouse monoclonal antibodies specific for DENND1 A. V2 and methods for using the same are provided.
    Type: Application
    Filed: November 19, 2014
    Publication date: October 13, 2016
    Applicants: Virginia Commonwealth University, The Penn State Research Foundation
    Inventors: Janette M. MCALLISTER, Jerome F. STRAUSS, Neil D. CHRISTENSEN
  • Publication number: 20160289187
    Abstract: Hybrid compounds of curcumin and melatonin as neuroprotectants are provided. The hybrid compounds are useful for the treatment and/or prevention of Alzheimer's disease (AD), as well as other neurodegenerative diseases. The hybrid compounds exhibited superior and potent neuroprotection in an AD model.
    Type: Application
    Filed: November 7, 2014
    Publication date: October 6, 2016
    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventor: Shijun Zhang
  • Patent number: 9457163
    Abstract: Ventilator associated pneumonia (VAP) may be prevented in a patient, or its occurrence reduced in a population of patients, by using an anti-VAP device or an anti-VAP material such as an anti-VAP mouthpiece that absorbs secretions. By reducing the problem of bacterial-containing secretions that otherwise build up in the airway of, and elsewhere in, the intubated patient, VAP can be prevented from occurring in intubated patients, such as patients intubated with an endotracheal tube (ETT) or a nasogastric tube. Anti-VAP mouthpieces also are useable in non-intubated patients to maintain oral hygiene.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: October 4, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Kevin R. Ward, Curtis N. Sessler, Mary Jo Grap, Laurence J. Dinardo, Bruce D. Spiess, Rao R. Ivatury, Cindy Muare
  • Patent number: 9421276
    Abstract: A polymer is provided, comprising a subunit having the formula: wherein A, B, C, D, a, b, c, d, and p are defined herein. Compositions, methods of making, and methods of use are provided.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: August 23, 2016
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Hu Yang, Olga Zolotarskaya, Kenneth J. Wynne, Kristoffer Valerie
  • Patent number: 9416016
    Abstract: Hyperhalogens, a new class of highly electronegative species, are now invented. A hyperhalogen is a superhalogen-containing composition in which the electron affinity (EA) of the hyperhalogen is even larger than that of the superhalogens they are composed of. Novel production methods are provided in which highly electronegative species are produced by surrounding a central metal atom by superhalogen moieties.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 16, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Puru Jena, Gerd Gantefoer
  • Publication number: 20160215167
    Abstract: A compound is provided, having the formula (I), wherein RS is a soft block polymer; wherein each T is independently a urethane or urea linkage; see formulae (A) and (B); wherein each RD is independently —CH3, —CH2CH3, —CH2CH2CH3, or —CH2CH2CH2CH3; wherein each R?D is independently —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, or —ORD; and wherein each p is independently 1, 2, or 3. Compositions containing the compound, and methods of making and using the compound are provided.
    Type: Application
    Filed: September 30, 2014
    Publication date: July 28, 2016
    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Kenneth J. WYNNE, Wei ZHANG
  • Patent number: 9399082
    Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: July 26, 2016
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Virginia Commonwealth University
    Inventors: Gary L. Bowlin, David G. Simpson, James R. Bowman, Stephen W. Rothwell
  • Patent number: 9399027
    Abstract: An organ protectant solution which is intravenously administered includes a high concentration of cell-impermeant molecules and at least one oncotic agent. The cell-impermeant molecules preferentially load into the interstitial space and the oncotic agent(s) is/are restricted to the vasculature space. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, and maintaining blood circulation and oxygenation of tissues. The organ protectant solution extends the “Golden Hour” for traumatic and/or hemorrhagic shock patients, thereby allowing more time for those patients to reach a point of care facility to receive medical treatment.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: July 26, 2016
    Assignee: Virginia Commonwealth University
    Inventor: Martin Mangino
  • Publication number: 20160201112
    Abstract: High sensitivity nanosensors for detecting the inhibition of glycosaminoglycan (GAG)-cleaving enzymes are provided. Methods of using the nanosensors include detecting contaminants in commercial GAG preparations (e.g. heparin preparations) by measuring the activity levels of a GAG)-cleaving enzyme in the presence of a sample which may contain a contaminant that inhibits the GAG-cleaving enzyme.
    Type: Application
    Filed: September 8, 2014
    Publication date: July 14, 2016
    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Umesh R. Desai, Mausam Kalita, Kuberan Balagurunathan
  • Patent number: 9376472
    Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: June 28, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Richard T. Marconi, Christopher Earnhart
  • Patent number: 9379162
    Abstract: Memory cells, non-volatile logic gates, and combinations thereof have magneto-tunneling junctions (MTJs) which are switched using potential differences across a piezoelectric layer in elastic contact with a magnetostrictive nanomagnet of an MTJ. One or more pairs of electrodes are arranged about the MTJ for supplying voltage across the piezoelectric layer for switching. A permanent magnetic field may be employed to change the positions of the stable magnetic orientations of the magnetostrictive nanomagnet. Exemplary memory cells and universal non-volatile logic gates show dramatically improved performance characteristics, particularly with respect to energy dissipation and error-resilience, over existing methods and architectures for switching MTJs such as spin transfer torque (STT) techniques.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: June 28, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Supriyo Bandyopadhyay, Jayasimha Atulasimha, Ayan Kumar Biswas
  • Patent number: 9364551
    Abstract: Conjugates are provided which comprise a membrane permeable drug linked to a moiety that is not membrane permeable. Attachment of the moiety that is not membrane permeable prevents the drug from crossing cell membranes and entering cells. However, exposure to light either i) breaks the linkage, releasing the drug and allowing it to enter cells; or ii) converts the non-membrane permeable moiety to a membrane permeable form, allowing the entire conjugate to enter the cell, where the drug is released from the conjugate by cleavage. The membrane permeable drugs are thus delivered to cells at locations of interest, e.g. cancer cells in a tumor, in a temporally and spatially controlled manner.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 14, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Matthew Hartman, Martin Michael Dcona, Deboleena Mitra
  • Patent number: 9364183
    Abstract: A glucometer guide is provided to address the difficulty that blind or visually impaired diabetic patients have when attempting to independently use a glucometer. The guide provides haptic cues for the effective transfer of blood onto a test strip.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: June 14, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Jacob Park, Matthew Standard, Dianne Pawluck, Linda Thurby-Hay, John Clore, Amber Spain
  • Publication number: 20160159653
    Abstract: New nanoparticles are provided which may have blocking temperatures exceeding 570 K even for particles as small as 8 nm in size. First principles theoretical investigations show that the new behavior is rooted in the giant magnetocrystalline anisotropies due to controlled mixing between carbon p-states and cobalt d-states. Furthermore, assemblies of the new nanoparticles may provide rare earth free permanent magnets having magnetic properties which rival those of rare earth permanent magnets.
    Type: Application
    Filed: March 27, 2014
    Publication date: June 9, 2016
    Applicant: Virginia Commonwealth University
    Inventors: Everett Carpenter, Ahmed A. El-Gendy, Shiv Khanna
  • Patent number: 9339241
    Abstract: Real-time, short-term analysis of ECG, by using multiple signal processing and machine learning techniques, is used to determine counter shock success in defibrillation. Combinations of measures when used with machine learning algorithms readily predict successful resuscitation, guide therapy and predict complications. In terms of guiding resuscitation, they may serve as indicators and when to provide counter shocks and at what energy levels they should be provided as well as to serve as indicators of when certain drugs should be provided (in addition to their doses). For cardiac arrest, the system is meant to run in real time during all current resuscitation procedures including post-resuscitation care to detect deterioration for guiding care such as therapeutic hypothermia.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: May 17, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Kayvan Najarian, Sharad Shandilya, Kevin R. Ward
  • Patent number: 9321802
    Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: April 26, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Shunlin Ren, William M. Pandak
  • Patent number: 9308414
    Abstract: A robotic module which can be attached to an exercise apparatus provides enhanced physical therapy for victims of stroke or other maladies or accidents by simulating normal or arbitrarily modified profiles of angular position of an extremity such as a foot in accordance with a position of that extremity along a locus of repetitive motion.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: April 12, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Peter E. Pidcoe, Jessica Cortney Bradford
  • Patent number: 9283244
    Abstract: Inhibitors of Late SV-40 Factor (LSF) are used to treat cancers such as hepatocellular carcinoma (HCC). In particular, small molecule chemical LSF inhibitors are employed. In addition, the activity and/or pattern of expression of LSF may is used to diagnose cancer, to characterize the cancer (e.g. stage, grade, prognosis, etc.) and also to develop suitable protocols for cancer treatment.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: March 15, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Devanand Sarkar, Paul B. Fisher
  • Patent number: 9271738
    Abstract: Bleeding from blood vessels located in difficult-to-compress regions of the body (especially the abdomen, pelvic or groin region) is controlled by the use of a portable, small-footprint belt-like device that contains multiple inflatable bladders. The inflatable bladders are selectively positioned and inflated over exsanguinating blood vessels, thereby exerting pressure to stop the bleeding. The device may also be used to provide perfusion support in low flow disease states such as hemorrhagic shock and cardiac arrest.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 1, 2016
    Assignee: Virginia Commonwealth University
    Inventors: Kevin R. Ward, Mark Licata